Benitec Biopharma (BNTC) Share-based Compensation (2019 - 2025)

Benitec Biopharma has reported Share-based Compensation for 7 years, with the latest figure at $37.8 million in Q4 2025.

• Quarterly Share-based Compensation rose 1104.59% year-over-year to $37.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $37.8 million (up 795.95% YoY) and the FY2025 annual result came in at $17.4 million, up 1999.52% from the prior year.
• Share-based Compensation rose to $37.8 million in Q4 2025 per BNTC's latest filing, from $5.2 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $37.8 million in Q4 2025 and troughed at -$92000.0 in Q1 2022.
• A 5-year average of $3.3 million and a median of $275000.0 in 2021 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2024: Share-based Compensation tumbled 139.15% in 2022, then jumped 3274.19% in 2024.
• Over 5 years, Share-based Compensation stood at $523000.0 in 2021, then sank by 109.18% to -$48000.0 in 2022, then jumped by 293.75% to $93000.0 in 2023, then surged by 3274.19% to $3.1 million in 2024, then soared by 1104.59% to $37.8 million in 2025.
• According to Business Quant data, Share-based Compensation over the past three periods registered $37.8 million, $5.2 million, and $13.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.